According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.
Lab Study Suggests Zinc May Worsen Rheumatoid Arthritis
NEW YORK (Reuters Health)—Zinc supplementation may exacerbate rheumatoid arthritis (RA), new laboratory data suggest. In monocytes from patients with RA, researchers found high concentrations of intracellular zinc, which regulates immune responses by affecting signaling pathways, according to a report in Science Signaling.1 They also found increased expression of Zip8, a zinc-specific importer, in peripheral and…
Insights into JAK Inhibitor Use
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
HCQ/CQ May Increase the Risk of Cardiovascular Events
A special article in the December issue of Arthritis & Rheumatology summarizes the current understanding of the cardiac toxicity of HCQ and CQ.
Tackling Multicomplexity in Aging Patients with RA
Two sessions at ACR Convergence 2021 addressed a holistic approach to taking care of older patients with RA & other rheumatic diseases.
Dusty Trades: Inorganic Dust Exposure During Military Service May Be an Occupational Risk Factor for RA
Mounting evidence indicates that exposure to inorganic dust is a risk factor for the development of autoimmune diseases. According to a recent study, dust exposure during military service in dusty environments represents an occupational and environmental risk and was associated with a 10% increased risk of developing RA.
The Role of ANA Positivity in Patients with RA
Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses.
Nonserious Infection Rates with Biologics Used to Treat RA
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.
20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 30
- Next Page »